NCT05975203

Brief Summary

The goal of this randomized controlled trial is to compare the effect of direct skin-to-skin contact in moderate and late preterm infants. The main questions it aims to answer are:

  • does skin-to-skin contact in moderate and late preterm infants influence gene expression in the stress signaling pathway?
  • does skin-to-skin contact in moderate and late preterm infants improve the short- and long-term outcome? Participants will either get immediate separation after vaginal birth or receive immediate skin-to-skin contact. Researchers will compare these two groups to answer the proposed questions.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
32mo left

Started Aug 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Aug 2023Dec 2028

First Submitted

Initial submission to the registry

July 13, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

August 3, 2023

Completed
1 day until next milestone

Study Start

First participant enrolled

August 4, 2023

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

February 20, 2026

Status Verified

October 1, 2025

Enrollment Period

3.4 years

First QC Date

July 13, 2023

Last Update Submit

February 18, 2026

Conditions

Keywords

preterm behavioral epigeneticsskin-to-skin contact

Outcome Measures

Primary Outcomes (3)

  • gene expression in candidate genes of the stress signalling pathway

    DNA will be extracted from peripheral white blood cells and mucosal epithelial cells. The expression of candidate genes of the stress signaling pathways are investigated. The candidate genes are glucocorticoid receptor (NR3C1), corticotropin releasing hormone (CRH), corticotropin-releasing hormone receptor 1 and 2 (CRHR1/2), serotonin transporter (slc6a4), vasopressin and brain-derived neurotrophic factor.

    36 to 72 hours after birth

  • gene expression in candidate genes of the stress signalling pathway

    DNA and RNA will be extracted from mucosal epithelial cells. The expression of candidate genes of the stress signaling pathways are investigated. The candidate genes are glucocorticoid receptor (NR3C1), corticotropin releasing hormone (CRH), corticotropin-releasing hormone receptor 1 and 2 (CRHR1/2), serotonin transporter (slc6a4), vasopressin and brain-derived neurotrophic factor. Furthermore a whole-genome methylation will be analysed.

    corrected 6 months of age

  • gene expression in candidate genes of the stress signalling pathway

    DNA will be extracted from mucosal epithelial cells. The expression of candidate genes of the stress signaling pathways are investigated. The candidate genes are glucocorticoid receptor (NR3C1), corticotropin releasing hormone (CRH), corticotropin-releasing hormone receptor 1 and 2 (CRHR1/2), serotonin transporter (slc6a4), vasopressin and brain-derived neurotrophic factor.

    corrected 24 months of age

Secondary Outcomes (10)

  • mother-child-interaction

    corrected 6 months of age

  • General Movements

    corrected 3 months of age

  • maternal depression

    at inpatient discharge (assessed from 3 to 60 days of life), corrected 6 and 24 months of age

  • social support

    at inpatient discharge (assessed from 3 to 60 days of life), corrected 24 months of age

  • socio-economic status

    at inpatient discharge (assessed from 3 to 60 days of life)

  • +5 more secondary outcomes

Study Arms (2)

Standard care

NO INTERVENTION

After delivery the infant will be separated from the mother and placed on a primary care unit in another room to monitor the cardiopulmonary adaption for at least 20 minutes.

skin-to-skin contact

EXPERIMENTAL

After delivery the infant will be put skin-to-skin on the mother's breast in comfort position for 60 minutes. The cardiopulmonary adaption will be monitored and supervised by the attending neonatologist and nurse.

Procedure: skin-to-skin contact

Interventions

Immediately after delivery the infant will receive skin-to-skin contact with the mother.

skin-to-skin contact

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • preterm birth between gestational age of 32 0/7 and 36 6/7 weeks
  • vaginal delivery
  • singleton
  • informed consent before birth

You may not qualify if:

  • malformations or syndromes of the infant
  • resuscitation of the infant
  • maternal psychological or severe physical illness
  • lack of German language skills

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University hospital of Cologne, Department of Neonatology

Cologne, Northrhine-westfalia, 50931, Germany

RECRUITING

Related Publications (2)

  • Mehler K, Hucklenbruch-Rother E, Trautmann-Villalba P, Becker I, Roth B, Kribs A. Delivery room skin-to-skin contact for preterm infants-A randomized clinical trial. Acta Paediatr. 2020 Mar;109(3):518-526. doi: 10.1111/apa.14975. Epub 2019 Sep 16.

    PMID: 31423649BACKGROUND
  • Hucklenbruch-Rother E, Vohlen C, Mehdiani N, Keller T, Roth B, Kribs A, Mehler K. Delivery room skin-to-skin contact in preterm infants affects long-term expression of stress response genes. Psychoneuroendocrinology. 2020 Dec;122:104883. doi: 10.1016/j.psyneuen.2020.104883. Epub 2020 Sep 24.

    PMID: 33027708BACKGROUND

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Katrin Mehler, PD Dr.

    University of Cologne

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katrin Mehler, PD Dr.

CONTACT

Angela Kribs, PD Dr.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Due to the nature of the intervention blinding of participant and care provider is not possible. The investigators are part of the care providing team.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 13, 2023

First Posted

August 3, 2023

Study Start

August 4, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2028

Last Updated

February 20, 2026

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations